Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

cis-platinum ototoxicity in children.

T R Pasic1, R A Dobie

  • 1Department of Otolaryngology, Head and Neck Surgery, University of Washington School of Medicine, Seattle.

The Laryngoscope
|September 1, 1991
PubMed
Summary

Cisplatin, an ototoxic chemotherapy, causes hearing loss in children. A 15-dB shift at 6-8 kHz indicates cisplatin ototoxicity, affecting 77% of pediatric patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Otologic injuries from airbag deployment.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery·2001
Same author

Efficacy of 3 commonly used hearing aid circuits: A crossover trial. NIDCD/VA Hearing Aid Clinical Trial Group.

JAMA·2000
Same author

Report of successful prolonged antifungal therapy for refractory allergic fungal sinusitis.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2000
Same author

A review of randomized clinical trials in tinnitus.

The Laryngoscope·1999
Same author

Calculating hearing handicap.

Journal of the American Academy of Audiology·1999
Same author

Low-level steady-state auditory evoked potentials: effects of rate and sedation on detectability.

The Journal of the Acoustical Society of America·1998

Area of Science:

  • Pediatric Oncology
  • Ototoxicology
  • Audiology

Background:

  • Cisplatin is a vital antineoplastic agent used in pediatric cancer treatment.
  • Cisplatin is known to cause ototoxicity, leading to hearing impairment.
  • Early identification of cisplatin-induced hearing loss is crucial for managing side effects.

Purpose of the Study:

  • To evaluate auditory thresholds in children treated with cisplatin.
  • To determine the cumulative dose of cisplatin associated with measurable hearing loss.
  • To establish a reliable criterion for identifying cisplatin ototoxicity.

Main Methods:

  • Auditory thresholds were assessed in 33 children receiving cisplatin.
  • Hearing evaluations focused on high-frequency thresholds (6 and 8 kHz).
  • Receiver-operator characteristic (ROC) curves were utilized to define ototoxicity criteria.

Main Results:

  • Hearing threshold shifts at 6 and 8 kHz became measurable after cumulative doses of 201-300 mg/m².
  • A 35-40 dB high-frequency threshold shift was observed with cumulative doses of 301-400 mg/m².
  • A 15-dB or greater average shift at 6 and 8 kHz identified cisplatin ototoxicity with 50% true-positive and 0% false-positive rates.

Conclusions:

  • Increasing cisplatin cumulative doses correlate with increased hearing loss severity.
  • Cisplatin ototoxicity was identified in 77% of pediatric patients using the 15-dB shift criterion.
  • The study provides a validated method for detecting cisplatin-induced hearing loss in children.

Related Experiment Videos